Anemia associated with chronic heart failure: Current concepts

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 111-122

  Shah, Ravish ^a   Agarwal, Anil K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anemia; Chronic kidney disease; Elderly population; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; CARVEDILOL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERROUS GLUCONATE; FERUMOXYTOL; IRON; IRON DERIVATIVE; IRON HYDROXIDE DEXTRAN; IRON HYDROXIDE SUCROSE; IRON SACCHARATE; METOPROLOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRACE ELEMENT; UNCLASSIFIED DRUG; VALSARTAN;

AGE DISTRIBUTION; ANEMIA; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL (TOPIC); COMORBIDITY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HEART FAILURE; HIGH RISK POPULATION; HUMAN; INFLAMMATION; IRON DEFICIENCY ANEMIA; KIDNEY DISEASE; LABORATORY TEST; LOW DRUG DOSE; MORBIDITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PROTEIN SYNTHESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ANEMIA; CHRONIC KIDNEY DISEASE; ELDERLY POPULATION; HEART FAILURE;

AGE FACTORS; AGED; ANEMIA; ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; ERYTHROPOIETIN; FEMALE; HEART FAILURE; HEMATINICS; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; IRON; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS;

EID: 84873653425     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S27105     Document Type: Review

References (73)

1. Spence RK. The economic burden of anemia in heart failure. Heart Fail Clin. 2010;6:373-383.
2. Tang WH, Yeo PS. Epidemiology of anemia in heart failure. Heart Fail Clin. 2010;6:271-278.
3. Blanc B, Finch CA, Hallberg L, et al. Nutritional anemias. Report of a WHO Scientific Group. WHO Tech Rep Ser. 1968;405:1.
4. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006;107: 1747-1750.
5. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;5:S1-S3.
6. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19:Ii1-Ii47.
7. Kidney Disease: Improving Global Outcomes. Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:288-291.
8. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in patients with heart failure a systematic review and meta-analysis. J Am Coll Radiol. 2008;52:818-827.
9. Adams KF Jr, Patterson JH, Oren RM, et al. Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINAHFP) Registry. Am Heart J. 2009;157:926-932.
10. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107:223-225.
11. Tanner H, Moschovitis G, Kuster GM, et al. The prevalence of anemia in chronic heart failure. Int J Cardiol. 2002;86:115-121.
12. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1440-1446.
13. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005;112:1121-1127.
14. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107:226-229.
15. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Cardiol. 2006; 48:2485-2489.
16. Allen LA, Felker GM, Mehar MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker of heart failure. J Card Fail. 2010;16:230-238.
17. Dec WC. Anemia and iron deficiency-new therapeutic targets in heart failure? N Engl J Med. 2009;361:2475-2477.
18. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
19. Testa M, Yeh M, Fanelli R, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease and hypertension. J Am Coll Cardiol. 1996;28:964-971.
20. Ganz T. Hepcidin: a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783-788.
21. Anand IS. Anemia and chronic heart failure: implication and treatment options. J Am Coll Cardiol. 2008;52:501-511.
22. Bolger AP, Doehner W, Sharma R, et al. Anaemia in chronic heart failure: the relationship to inflammatory cytokine expression and prognostic importance. Circulation. 2002;106:570-571.
23. Balducci L, Hardy CL, Lyman GH. Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control. 2000;7:539-547.
24. Bommer J. Saving erythropoietin by administering l-carnitine? Nephrol Dial Transplant. 1999;14:2819-2821.
25. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26: 2232-2237.
26. Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production but to fluid retention as well. Eur Heart J. 2007;28:166-171.
27. Le Jemtel TH, Arain S. Mediators of anemia in chronic heart failure. Heart Fail Clin. 2010;6:289-293.
28. Vander Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112: 1743-1747.
29. Bernstein KE, Xiao HD, Frenzel K, et al. Six truisms concerning ACE and the renin-angiotensin system educed from the genetic analysis of mice. Circ Res. 2005;96:1135-1144.
30. Alexandrakis MG, Tsirakis G. International Scholarly Research Network. Hematology. 2012.
31. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA. 1999;281:1714-1717.
32. Price EA, Mehra R, Holmes TH, Schrier SL. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis. 2011;46;159-165.
33. Tang YD, Katz SD. Anemia in chronic heart failure. Prevalence, etiology, clinical correlates and treatment options. Circulation. 2006; 113:2454-2461.
34. Guralnik JM, Ershler WB, Schrier SL, Picozzi VJ. Anemia in the elderly: a public health crisis in hematology. Hematology Am Soc Hematol Educ Program. 2005:528-532.
35. Guralnik JM, Eisenstaedt RS, Klein HG, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104:2263-2268.
36. Horwich TB, Foranow GC, Hamilton MA, et al. Anemia is associated with symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
37. Kosiborod M, Curtis JP, Wang Y, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med. 2005;165:2237-2244.
38. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure. The Anemia in Chronic Heart Failure: Outcomes and Resources Utilization (ANCHOR) study. Circulation. 2006;113: 2713-2723.
39. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48: 2485-2489.
40. Beck SL, Rohde LE, Clausell N. Etiology and management of anemia in patients with heart failure: how much iron is missing? Congest Heart Fail. 2008;14:25-30.
41. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975-984.
42. Agarwal AK, Singh A. Therapy with erythropoiesis-stimulating agents and renal and non-renal outcomes. Heart Fail Clin. 2010;6:323-332.
43. Glaspy J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology. 1999;13:461-473.
44. MacDougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61-S66.
45. Pasricha SR, Flecknoe-Brown SC, Allen KJ, et al. Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust. 2010;193:525-532.
46. Von Haehling S, Anker MS, Jankowska EA, et al. Anemia in chronic heart failure: can we treat? What to treat? Heart Fail Rev. 2012;17: 203-210.
47. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematol Am Soc Hematol Educ Program. 2010: 338-347.
48. Bhandari S. Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care. Nephrol Dial Transplant. 2011;4:i14-i19.
49. MacDougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin receptor agonist for pure red-cell aplasia. N Engl J Med. 2009; 361:1848-1855.
50. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225-1227.
51. Toblli JE, Lombraña A, Duarte P, Di Genarro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemia patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657-1665.
52. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103-112.
53. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. w Engl J Med. 2009;361:2436-2448.
54. Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic heart failure (FAIRHF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail. 2009;11:1084-1091.
55. Eschbach JW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol. 2000;20:320-329.
56. Kansagara D, Dyer EAW, Englander H, Freeman M, Kagen D. Treatment of anemia in patients with heart disease: a systematic review. VA-ESP Project 05-225; 2011.
57. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
58. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355: 2085-2098.
59. Pfeffer MA, Burdmann EA, Chen CY, et al. Atrial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361: 2019-2032.
60. Dicato M. Venous thromboembolic events and erythropoiesis stimulating agents: an update. Oncologist. 2008;13:11-15.
61. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
62. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49:753-762.
63. Ghali JK, Anand IS, Abraham WT, et al. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008:117:526-535.
64. Vander Meer P, Groenveld HF, Januzzi JL, et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart. 2009;95:1309-1314.
65. Parissis JT, Kourea K, Panou F, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751.
66. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:1096.
67. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208-2216.
68. Geisler BP, van Dam RM, Gazelle GS, et al. Risk of bias in meta-analysis on erythropoietin-stimulating agents in heart failure. Heart. 2009;95:1278-1279.
69. McMurray JJ, Anand IS, Diaz R, etal; RED-HF Committees and Investigators. Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009;11:795-801.
70. Maurer MS. Efficacy of treating anemia in heart failure with a preserved ejection fraction (HFPEF) on ventricular function, exercise capacity and health status. ClinicalTrials. gov Identifier: NCT00286182.
71. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
72. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780.
73. Comín-Colet J, Ruiz S, Cladellas M, Rizzo M, Torres A, Bruguera J. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardiorenal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Cardiac Fail. 2009;15:727-735.